CASI Pharmaceuticals (CASIF) Non-Current Debt (2021 - 2024)

CASI Pharmaceuticals has reported Non-Current Debt for 4 years, with the latest figure at $18.5 billion in Q2 2024.

• For the quarter ending Q2 2024, Non-Current Debt changed N/A year-over-year to $18.5 billion; the trailing twelve-month figure through Jun 2024 stood at $18.5 billion (changed N/A YoY), and the FY2023 full-year result was $18.9 billion, up 159742.65% from the prior year.
• Non-Current Debt for Q2 2024 stood at $18.5 billion, up from $18.6 million in the prior quarter.
• The five-year high for Non-Current Debt was $18.9 billion in Q4 2023, with the low at $11.8 million in Q4 2022.
• Historically, Non-Current Debt has averaged $7.5 billion across 4 years, with a median of $18.6 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Debt retreated 10.58% — and 2023, when it soared 159742.65%.
• CASI Pharmaceuticals' Non-Current Debt stood at $13.2 million in 2021, then retreated by 10.58% to $11.8 million in 2022, then soared by 159742.65% to $18.9 billion in 2023, then declined by 2.28% to $18.5 billion in 2024.
• The last three Non-Current Debt figures came in at $18.5 billion (Q2 2024), $18.6 million (Q1 2024), and $18.9 billion (Q4 2023), per Business Quant data.